$303 Million is the total value of Fairmount Funds Management LLC's 20 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZGNX | Buy | ZOGENIX INC | $40,662,000 | +37.8% | 2,502,259 | +28.8% | 13.40% | +24.9% |
| INSM | INSMED INC | $35,783,000 | -1.1% | 1,313,607 | 0.0% | 11.80% | -10.3% | |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $28,970,000 | +60.9% | 387,400 | +22.2% | 9.55% | +45.8% |
| ARGX | Buy | ARGENX SEsponsored adr | $27,540,000 | +55.5% | 78,644 | +34.1% | 9.08% | +41.0% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $21,748,000 | +241.4% | 743,000 | +197.2% | 7.17% | +209.6% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $18,665,000 | +20.2% | 944,092 | 0.0% | 6.15% | +9.0% | |
| NUVALENT INC | $17,414,000 | -15.6% | 914,614 | 0.0% | 5.74% | -23.5% | ||
| KROS | Buy | KEROS THERAPEUTICS INC | $17,134,000 | +190.0% | 292,833 | +96.1% | 5.65% | +163.0% |
| COGT | COGENT BIOSCIENCES INC | $13,376,000 | +2.0% | 1,558,975 | 0.0% | 4.41% | -7.5% | |
| TIL | INSTIL BIO INC | $11,531,000 | -4.3% | 673,905 | 0.0% | 3.80% | -13.2% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $9,729,000 | +40.5% | 416,817 | 0.0% | 3.21% | +27.4% | |
| Buy | TYRA BIOSCIENCES INC | $9,080,000 | +3.4% | 645,349 | +29.3% | 2.99% | -6.2% | |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $8,509,000 | +0.6% | 1,519,382 | +38.2% | 2.80% | -8.8% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $8,419,000 | -34.2% | 2,498,237 | -0.4% | 2.78% | -40.3% |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO | $7,669,000 | – | 55,647 | +100.0% | 2.53% | – |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $7,437,000 | -22.6% | 389,588 | 0.0% | 2.45% | -29.8% | |
| AXSM | AXSOME THERAPEUTICS INC | $7,087,000 | +14.6% | 187,598 | 0.0% | 2.34% | +3.9% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $6,227,000 | +22.6% | 926,602 | 0.0% | 2.05% | +11.2% | |
| ASTRIA THERAPEUTICS INC | $4,914,000 | -39.0% | 911,736 | 0.0% | 1.62% | -44.7% | ||
| ALLK | Sell | ALLAKOS INC | $1,441,000 | -92.2% | 147,189 | -16.1% | 0.48% | -93.0% |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -886,281 | -100.0% | -5.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.